0001209191-23-050727.txt : 20230928 0001209191-23-050727.hdr.sgml : 20230928 20230928161728 ACCESSION NUMBER: 0001209191-23-050727 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230928 FILED AS OF DATE: 20230928 DATE AS OF CHANGE: 20230928 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Jakeman David CENTRAL INDEX KEY: 0001780556 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35867 FILM NUMBER: 231289909 MAIL ADDRESS: STREET 1: C/O CHIMERIX, INC., STREET 2: 2505 MERIDIAN PARKWAY, SUITE 100 CITY: DURHAM STATE: NC ZIP: 27713 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CHIMERIX INC CENTRAL INDEX KEY: 0001117480 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330903395 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2505 MERIDIAN PARKWAY, SUITE 100 CITY: DURHAM STATE: NC ZIP: 27713 BUSINESS PHONE: 919.806.1074 MAIL ADDRESS: STREET 1: 2505 MERIDIAN PARKWAY, SUITE 100 CITY: DURHAM STATE: NC ZIP: 27713 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-09-28 0 0001117480 CHIMERIX INC CMRX 0001780556 Jakeman David C/O CHIMERIX, INC. 2505 MERIDIAN PARKWAY, SUITE 100 DURHAM NC 27713 0 1 0 0 VP of Finance and Accounting 0 Common Stock 2023-09-28 4 S 0 3610 0.9927 D 133142 D The shares were sold in payment of the reporting person's tax liability incurred upon the vesting of shares subject to a restricted stock unit award granted on September 26, 2019. The sales of the shares were made pursuant to an automatic sell-to-cover arrangement adopted pursuant to Rule 10b5-1 under the Exchange Act in connection with the grant of such restricted stock unit award. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9753 to $0.9966, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. /s/ Michael Alrutz, Attorney-in-Fact 2023-09-28